| 引用本文:周 杰1 吴燕梅1 刘珊珊1 赵志刚2 秦贵军3 田晨光4.糖尿病治疗药物的药物经济学研究[J].世界中医药,2013,8(08):. |
|
| 糖尿病治疗药物的药物经济学研究 |
| Study on the Pharmacoeconomics of Diabetes Medication |
| 投稿时间：2013-03-11 |
| DOI：10.3969/j.issn.1673-7202.2013.08.037 |
| 中文关键词: 药物经济学 安全性 有效性 C/E 总花费/HbA1c 消渴丸 瑞格列奈 格列吡嗪 二甲双胍 |
| English Keywords:pharmaceutical economics safety efficacy C/E total cost /HbA1c Xiaoke pill Repaglinide Glipizide Metformin |
| 基金项目: |
|
| 摘要点击次数: 1225 |
| 全文下载次数: 1211 |
| 中文摘要: |
| 目的：采取不同口服降糖药，组成价格不等的治疗方案，比较方案的经济学、有效性和安全性的差异，探讨消渴丸在药物经济学方面的优势。方法：选取糖尿病患者296例，随机分为4组，采取4种治疗方案，观察4组患者的临床效果及成本效果。结果：在安全性和有效性方面，4种治疗方案没有统计学意义，在药物经济学研究上，二甲双胍的C/E和总花费/HbA1c比率最低，可以认为最为经济，消渴丸次之，再次为格列吡嗪和瑞格列奈。结论：从药物有效性、经济性和安全性方面综合考虑，2型糖尿病的起始降糖治疗用药可选择二甲双胍或消渴丸，必要时两药联合；通过有效的管理有助于节省成本，改善血糖控制水平。 |
| English Summary: |
| Take different oral hypoglycemic drugs to compose different therapeutic schemes， and compare the differences among these therapeutic schemes in terms of economics， efficacy and safety. Discuss the advantages of Xiaoke pill in pharmacoeconomic aspects. Methods: A total of 296 cases of patients with diabetes mellitus were randomly divided into four groups， and adopted four kinds of treatment.Observe the clinical efficacy and cost effectiveness of the four groups of patients. Results: The four therapeutic schemes had no significant difference in efficacy or safety. In the study of pharmaceutical economics， Metformin group had the lowest rate of C/E and total cost /HbA1c. Xiaoke pill group ranked second， followed by Glipizide group and Repaglinide group. Conclusion: Considering the efficacy， safety and economy aspects， metformin or Xiaoke pill can be used for initial therapy for type-2 diabetes. Combination of the two can also be used if necessary. Through effective management， it helps to save cost and improve the level of blood glucose control. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
